[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@][C][C@@H1][Branch2][Ring2][#C][C@][Branch2][Ring2][#Branch2][C@H1][Branch2][Ring1][Branch1][C@@H1][Ring1][=Branch1][C][C@H1][Branch1][=N][C@@][Ring1][=Branch2][Branch1][#Branch1][C][=Branch1][C][=O][C][O][O][O][C][C][C][=C][C][=Branch1][C][=O][C][=C][C@@][Ring1][#Branch1][Ring2][Ring1][Branch1][C][F][O]"}, {"from": "gpt", "value": "The molecule is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.  Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis."}]